nav-left cat-right
cat-right

CHIKUNGUNYA VACCINE DEVELOPMENT TOWARDS PHASE III ...

Vienna, 5th September 2017 – The further development of a promising Chikungunya vaccine candidate by Themis Bioscience is now supported with 3 Mio. GBP by the United Kingdom’s innovation agency, Innovate UK. Themis, the Vienna-based specialist for vaccine development, will use these funds to identify and validate a correlate of protection for its prophylactic Chikungunya vaccination candidate. Currently the candidate...

3rd Allergy, Asthma, & COPD Conference Januar...

GTCbio is delighted to present the 3rd Allergy, Asthma, & COPD Conference, to be held on January 25-26, 2016 in San Diego, CA. The conference will bring together industry, academia and government experts in the field of allergy, asthma and COPD. Experts will facilitate discourse on the challenges and opportunities for therapeutic and drug development for allergic diseases for the current and future generations. Topics...

Enzymes in Drug Discovery Summit February 29 ̵...

We are excited to announce the Enzymes in Drug Discovery Summit, which will take place February 29 – March 2, 2016 in San Diego, CA. Enzymes have proven to be an important group of drug targets in diseases, and enzyme inhibitors have been among the most successful of drugs. Join us as we discuss ways to overcome drug resistance to these inhibitors, and discuss breakthroughs in targeting historically undruggable...

2nd Next Generation Sequencing & Bioinformati...

We welcome you to join us at GTCbio’s 2nd Next Generation Sequencing & Bioinformatics Conference on October 5-7, 2015 in Berlin, Germany. This conference gathers the foremost experts to present on leading-edge technology in next-generation sequencing and bioinformatics featuring discussions on opportunities and challenges in NGS, bioinformatics, and data management. Join your peers in this one-of-a-kind opportunity to...

Seegene Receives FDA Clearance for its Herpes Simp...

Gaithersburg, Maryland and SEOUL, Korea, February 17, 2015 – Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) market clearance for its TOCE™-based herpes simplex virus (HSV) types 1 and 2 assay. This is the first product that Seegene has taken through the FDA, and it opens the way for Seegene’s other...

Pan Omics Summit May 21-22,2015 Boston, MA

We invite you to the attend the Pan-Omics Summit, which will take place May 21 – 22, 2015 in Boston, MA at the Hyatt Regency. This summit has four parallel tracks to discuss the developments and challenges in the popular omics areas of epigenomics, metabolomics, functional genomics, and next generation sequencing. Representatives from big pharma, academic institutions, and government research labs will present data on...
Page 1 of 712345...Last »